Pharmaceuticals Stocks

Celgene Corporation Stock Analysis – May 2015 Quarterly Update

Celgene Corporation is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the lack of earnings stability over the last ten years, the lack of dividends, as well as the high PEmg and PB ratios, while the Enterprising Investor has no initial concerns.

Read More
Feature Value Investing Weekly

28 Companies in the Spotlight This Week – 2/28/15

We evaluated 28 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.

Read More
Pharmaceuticals Stocks

Celgene Corporation Quarterly Valuation – February 2015 $CELG

Celgene is suitable for the Enterprising Investor, but not the more conservative Defensive Investor, who is concerned with the lack of dividends, lack of earnings stability over the last ten years, as well as the high PEmg and PB ratios. The Enterprising Investor, on the other hand, is only concerned by the lack of dividends.

Read More
Feature Value Investing Weekly

30 Companies in the Spotlight This Week – 11/15/14

We evaluated 30 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.

Read More
Back To Top